<p>一系列不利因素导致下一代医疗公司 <strong>BioNTech</strong>(BNTX -6.58%) 在股市上遭遇不佳表现。投资者对公共卫生领域最新的高层任命表示担忧，同时一位分析师对该公司的未来变得更加悲观。</p>
<p>烟雾散去后，BioNTech 的股价当天收盘下跌超过 6%。这一跌幅比 <strong>S&amp;P 500</strong> 指数的 0.8% 下跌更为剧烈。</p>
<h2>有争议的任命</h2>
<p>美国食品药品监督管理局（FDA），隶属于由罗伯特·肯尼迪 Jr. 领导的政府卫生与人类服务部（HHS），于周二上午宣布了这一任命。它选择了维奈·普拉萨德博士担任其生物制品评估与研究中心的负责人，该中心负责批准疫苗。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MTc0MTgvcGVyc29uLWFib3V0LXRvLXJlY2VpdmUtYS12YWNjaW5lLXNob3QuanBnJnc9NzAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MTc0MTgvcGVyc29uLWFib3V0LXRvLXJlY2VpdmUtYS12YWNjaW5lLXNob3QuanBnJnc9NzAw"/></p>
<p>图片来源：Getty Images。</p>
<p>这一举动颇具争议，因为普拉萨德在 COVID-19 大流行期间因对抗击疫情政策的尖锐批评而声名鹊起。</p>
<p>在公告发布后，许多正在开发或已上市疫苗的上市公司股价下跌，其中包括 BioNTech。</p>
<h2>目标价下调</h2>
<p>在时机不佳的情况下，周一市场收盘后，<strong>花旗集团</strong> 的杰夫·米查姆下调了该公司股票的目标价。在周一上午发布的第一季度财报后，米查姆将其公允价值评估从之前的 145 美元调整为每股 140 美元。</p>
<p>据报道，米查姆表示，目前美国在呼吸道疫苗方面的政策不稳定。然而，他对该公司第一季度的表现印象深刻，并认为其现金流良好，正在开发有前景的治疗方案。</p>
<p>尽管 BioNTech 最近的表现令人印象深刻，尤其是与 <strong>辉瑞</strong> 共同开发的 Comirnaty COVID-19 疫苗，但它仍是一家年轻的公司，需要推出更多产品以成为一个有吸引力的投资。尽管如此，这是一只值得关注的股票。</p>

BNTX

<p>BioNTech 的股票因对一项有争议的 FDA 任命和一份看跌的分析师报告的担忧而下跌超过 6%。FDA 任命了以批评 COVID-19 政策而闻名的 Dr. Vinay Prasad 来领导其疫苗部门，这对疫苗相关股票产生了影响。此外，花旗集团分析师 Geoff Meacham 将 BioNTech 的目标股价从 145 美元下调至 140 美元，理由是对美国呼吸道疫苗政策的不确定性，尽管他承认该公司第一季度表现强劲，且有令人期待的发展</p>

<p>An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company <strong>BioNTech</strong>(BNTX -6.58%). Investors were concerned about the latest top-level appointment in public health, plus an analyst became a bit more bearish about the company's future.</p>
<div class="lb-trans"><p>一系列不利因素导致下一代医疗公司 <strong>BioNTech</strong>(BNTX -6.58%) 在股市上遭遇不佳表现。投资者对公共卫生领域最新的高层任命表示担忧，同时一位分析师对该公司的未来变得更加悲观。</p>
</div><p>When the smoke cleared, BioNTech's shares closed the day more than 6% lower. That was a more dramatic slide than the 0.8% drop of the <strong>S&amp;P 500</strong> index.</p>
<div class="lb-trans"><p>烟雾散去后，BioNTech 的股价当天收盘下跌超过 6%。这一跌幅比 <strong>S&amp;P 500</strong> 指数的 0.8% 下跌更为剧烈。</p>
</div><h2>A controversial pick</h2>
<div class="lb-trans"><h2>有争议的任命</h2>
</div><p>The Food and Drug Administration (FDA), a division of the government's Department of Health and Human Sciences (HHS) headed by Robert Kennedy Jr., announced that appointment Tuesday morning. It has selected Dr. Vinay Prasad to head its Center for Biologics Evaluation and Research, the division responsible for approving vaccines.</p>
<div class="lb-trans"><p>美国食品药品监督管理局（FDA），隶属于由罗伯特·肯尼迪 Jr. 领导的政府卫生与人类服务部（HHS），于周二上午宣布了这一任命。它选择了维奈·普拉萨德博士担任其生物制品评估与研究中心的负责人，该中心负责批准疫苗。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MTc0MTgvcGVyc29uLWFib3V0LXRvLXJlY2VpdmUtYS12YWNjaW5lLXNob3QuanBnJnc9NzAw" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F817418%2Fperson-about-to-receive-a-vaccine-shot.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><p>This is a controversial move, as Prasad came to prominence during the COVID-19 pandemic as an often sharp critic of policies enacted to fight the disease.</p>
<div class="lb-trans"><p>这一举动颇具争议，因为普拉萨德在 COVID-19 大流行期间因对抗击疫情政策的尖锐批评而声名鹊起。</p>
</div><p>Following the announcement, prices dropped for numerous publicly traded companies that are either developing or have marketed vaccines -- BioNTech among them.</p>
<div class="lb-trans"><p>在公告发布后，许多正在开发或已上市疫苗的上市公司股价下跌，其中包括 BioNTech。</p>
</div><h2>Price target shaved</h2>
<div class="lb-trans"><h2>目标价下调</h2>
</div><p>In what's a case of bad timing, after market hours on Monday <strong>Citigroup</strong>'s Geoff Meacham cut his price target on the company's stock. Following its first-quarter earnings report (published Monday morning), Meacham changed his fair value assessment to $140 per share from his preceding $145.</p>
<div class="lb-trans"><p>在时机不佳的情况下，周一市场收盘后，<strong>花旗集团</strong> 的杰夫·米查姆下调了该公司股票的目标价。在周一上午发布的第一季度财报后，米查姆将其公允价值评估从之前的 145 美元调整为每股 140 美元。</p>
</div><p>According to reports, Meacham wrote that current U.S. policy on respiratory vaccines is shaky. However he was impressed with the company's first-quarter performance, and feels it has a good cash runway and promising treatments in development.</p>
<div class="lb-trans"><p>据报道，米查姆表示，目前美国在呼吸道疫苗方面的政策不稳定。然而，他对该公司第一季度的表现印象深刻，并认为其现金流良好，正在开发有前景的治疗方案。</p>
</div><p>While BioNTech does have an impressive recent past, notably with the Comirnaty COVID-19 vaccine it developed with <strong>Pfizer</strong>, it's still a young company that needs to bring more products to market to be a compelling investment. That said, it's a stock well worth keeping an eye on.</p>
<div class="lb-trans"><p>尽管 BioNTech 最近的表现令人印象深刻，尤其是与 <strong>辉瑞</strong> 共同开发的 Comirnaty COVID-19 疫苗，但它仍是一家年轻的公司，需要推出更多产品以成为一个有吸引力的投资。尽管如此，这是一只值得关注的股票。</p>
</div>

Why BioNTech Stock Got Trounced on Tuesday

- BioNTech 股价因公共卫生高层任命及分析师看空而下跌超过 6%。  
- FDA 任命 Dr. Vinay Prasad 负责疫苗审批，引发争议。  
- Citigroup 下调 BioNTech 目标价至 140 美元，反映市场对呼吸道疫苗政策的不确定性。

为什么 BioNTech SE 的股票在周二遭遇重创